FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasilington,	D.C.	20040

TATEMENT (OF CH	IANGE

S ES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* LILLY ENDOWMENT INC					2. Issuer Name and Ticker or Trading Symbol ELI LILLY & Co [LLY]							Relationship of Reporting Person(s) to Issuer (Check all applicable) Director							
(Last) 2801 NC	(Fir	est) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 08/04/2021							Office below	er (give title /)		Other (s	specify			
(Street) INDIANAPOLIS IN 46208-0068				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(Sta	ate) (2	Zip)										Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yo	ear) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					d 5)	Securi Benefi Owned	cially I Following	6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)		
Common	Stock		08/04/202	1			S		369	D	\$260.	191 ⁽¹⁾	108,	525,189		D			
Common	Common Stock 08/04/202		1	ı		S		352	D	\$261.	589 ⁽²⁾	108,	,524,837		D				
Common	Common Stock 08/04/202		1			S		1,214	D	\$262.	741 ⁽³⁾	108,	,523,623		D				
Common	mon Stock 08/04/202		1			S		2,210	D	\$263	.48(4)	108,	,521,413		D				
Common	ommon Stock 08/04/202		1			S		2,410	D	\$264.	525 ⁽⁵⁾	108,	3,519,003		D				
Common	mmon Stock 08/04/202		1			S		2,430	D	\$265.52 ⁽⁶⁾		108,	108,516,573		D				
Common	Common Stock 08/04/202		1			S		2,409	D	\$266.695 ⁽⁷⁾		108,514,164			D				
Common	ommon Stock 08/04/202		1			S		1,085	D	\$267.763(8)		108,513,079			D				
Common	nmon Stock 08/04/202		1			S		679	D	\$268.	543 ⁽⁹⁾	108,	108,512,400		D				
Common Stock 08/04/202			1		S		300	D	\$269.8	369(10)	108,512,100			D					
		Tal	ble II - Derivat										Dwne	t					
1. Title of 2. 3. Transaction Date Execution Date Security or Exercise (Month/Day/Year) if any			3A. Deemed Execution Date,	4. Transaction Code (Instr. 8)		5. Numl of Derivati Securiti Acquire (A) or Dispose of (D) (Instr. 3 and 5)	oer 6. Ex (ve (es ed	ptions, convertib Date Exercisable and expiration Date Month/Day/Year)		7. Ti Amo Sec Und Deri Sec	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		rice of ivative curity etr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Beneficial Ownership (Instr. 4)		
				Code	v	(A) (I		ite ercisa	Expiratio	n Title	Amou or Numb of Share	er							
Explanatio	n of Respons	ses:																	

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$259.7119 to \$260.59, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), and (10) to this Form 4.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$261.0537 to \$261.8898, inclusive.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$262.06 to \$263.05, inclusive.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$263.06 to \$264.0296, inclusive.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$264.0783 to \$265.0472, inclusive. 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$265.0931 to \$266.0919, inclusive.
- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$266.147 to \$267.1199, inclusive.
- 8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$267.1545 to \$268.1217, inclusive.
- 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$268.1603 to \$269.0285, inclusive.
- 10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$269.2683 to \$270.25, inclusive.

Remarks:

/s/Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc.

08/05/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.